retatrutide expanded access program has not been approved by the FDA, but precisely one 79-year-old man was granted via "compassionate use." Retatrutide (LY-3437943) Market Analysis, 2033:

GLP-1 drugs may help with appetite and weight reduction, but they may also create clinically meaningful nutritional side effects, especially in patients with poor baseline diet quality, prolonged use, gastrointestinal side effects, or rapid weight loss

Lock, T

Depending on your weight loss goals, this potent addition to your routine can enable you to more quickly and easily while you sculpt your physique and enjoy higher energy levels, mood stabilization and improvement, and appetite reduction

RUO labeling does not shield a business from patent liability

10.1016/j.cell.2018.10.025 32 KobilkaB

by Richard Weil, M.Ed., CDE Founder and Director Transformation Weight Control I like to show the following slide when discussing side effects of GLP-1 receptor agonists